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CASE REPORT
A Case of Assisted Reproductive Therapy-induced 
Erythema Nodosum
Hye Chan Jeon, M.D., Mira Choi, M.D., Seung Hwan Paik, M.D., Sun Jae Na, M.D., 
Jong Hee Lee, M.D., Soyun Cho, M.D.
Department of Dermatology, Seoul National University Boramae Hospital, Seoul, Korea 
Erythema nodosum is a common variant of panniculitis. It is 
characterized by tender erythematous nodule and plaque on 
the anterior aspect of the leg. The etiology is not fully 
understood. It may be associated with a variety of disorders, 
including infection, medication, autoimmune disorders, 
pregnancy, and malignancy. A 33-year-old Korean woman 
presented with 1 week history of painful erythematous 
plaques on both knees. She was 7 weeks pregnant with 
assisted reproductive therapy, and had been maintained on 
daily intramuscular progesterone injection for 4 weeks. 
Histological examination of the lesions revealed septal 
panniculitis without vasculitis. Two days after discontinuing 
progesterone injection, the symptoms and lesions started to 
resolve. Herein we present a case of erythema nodosum 
caused by progesterone injection for endometrial pre-
paration. (Ann Dermatol 23(3) 362∼364, 2011)
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INTRODUCTION
Erythema nodosum is a common form of panniculitis. 
Typically, they are tender erythematous nodules and raised 
plaques on the anterior aspects of legs. The etiologic 
factors and pathogenesis are not yet fully understood. 
Erythema nodosum is associated with a variety of clinical 
conditions, including infection, medication, autoimmune 
disorders, pregnancy, and malignancy. It is well-known 
that the etiology of erythema nodosum is associated with 
female sex hormones - estrogen and progesterone
1. As 
pregnancies conceived through assisted reproductive the-
rapy increase, we predict that the incidence of erythema 
nodosum in women who underwent assisted reproductive 
therapy will increase. We herein report a case of erythema 
nodosum caused by progesterone injection for endo-
metrial preparation. 
CASE REPORT 
A 33 year-old Korean woman presented with a 1-week 
history of painful erythematous plaques on both knees. 
Physical examination showed symmetric, tender, erythe-
matous plaques on the anterior aspects of both knees (Fig. 
1A). Pain was aggravated by exercise, particularly during 
walking. Although the lesions were warm, she had no 
fever. She was systemically well in the seventh week of 
her first pregnancy. She had never used oral contracep-
tives. She had become pregnant after undergoing assisted 
reproductive therapy. Intramuscular injection of proges-
terone (50 mg) had been administered daily for to enable 
endometrial preparation for 4 weeks. There was no history 
of upper respiratory infection before her presentation. She 
had only received hormonal assisted reproductive therapy.
We noted thickened septa with infiltrated inflammatory 
cells without evidence of vasculitis (Fig. 2A). There were 
also inflammatory cells in the periseptal areas of the fat 
lobules (Fig. 2B).
We diagnosed our patient with erythema nodosum follow-
ing histopathological evaluation. Intramuscular progesterone A Case of ART-induced Erythema Nodosum
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Fig. 1. (A) Symmetric, tender, erythematous plaques on the anterior aspects of both knees. (B) Two days after discontinuing intramuscular 
progesterone injection, the color of the lesions became darker and then started to resolve.
Fig. 2. (A) Scanning power view showing thickened and edematous septa of the subcutaneous tissue with inflammatory infiltrate,
and the infiltrate extends to the periphery of the adjacent fat lobules (Lt. knee, H&E, ×40), (B) Higher magnification shows aggregations
of small histiocytes (Lt. knee, H&E, ×400). 
therapy was ceased and instead she began to receive 
vaginal topical progesterone (Crinone gel
Ⓡ). Two days 
after discontinuing intramuscular progesterone injection, 
clinical improvement was observed (Fig. 1B). The lesions 
started to resolve, and the color of lesions became darker 
and more brown. We added acetaminophen treatment. 
Progesterone continued to be administered for endometrial 
preparation in the following manner: 4 weeks intramus-
cularly and 3 weeks topically to the vagina. At the time of 
preparing this publication, there has been no evidence of 
recurrence. 
DISCUSSION
Erythema nodosum is the most frequent clinicopathologic 
variant of septal panniculitis
2. Since first described in 
1798, various etiologic factors have been identified: stre-
ptococcal infections, sarcoidosis, autoimmune disorders, 
inflammatory bowel diseases, drugs such as oral contra-
ceptives
3 and malignancy
1,4. Nevertheless, the etiology 
cannot be confirmed in 37 to 60% of cases of erythema 
nodosum
4.
In a prospective study of 132 patients diagnosed with 
erythema nodosum, hormonal factors during pregnancy HC Jeon, et al
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and oral contraceptives were the causes of  10% of cases
1. 
This is not the only evidence to suggest that female sex 
hormone is related to erythema nodosum. After puberty, 
erythema nodosum follows a female predominance, but 
before puberty, the sex incidence is approximately equal
4. 
In addition, there are cases of erythema nodosum in the 
course of hormone replacement therapy in postmeno-
pausal women
5 and after aromatase inhibitor admini-
stration in breast cancer patients
6.
If then, which factor of female sex hormones could cause 
erythema nodosum? The concentrations of these hormones 
are thought to be critical in the development of erythema 
nodosum
7. There was no report of erythema nodosum 
associated with high-dose estrogen salvage therapy for 
metastatic breast cancer, while low-dose hormone replace-
ment therapy in postmenopausal women can cause ery-
thema nodosum
5. Furthermore, erythema nodosum com-
monly occurs during the first trimester of gestation, but not 
in the third trimester. In addition, erythema nodosum has 
been observed in breast cancer patients treated with 
aromatase inhibitors, which suppresses plasma estrogen 
levels
6. This presented case demonstrates that sole 
progesterone therapy can cause erythema nodosum. The 
fact that skin lesions began to resolve after commencing 
topical progesterone, which led to reduction in serum 
progesterone concentration although not measured clini-
cally, is consistent with this hypothesis. Therefore, we 
suggest that the concentration of progesterone or the ratio 
between estrogen and progesterone is more important in 
the pathogenesis of erythema nodosum than the concen-
tration of estrogen alone. 
Keratinocytes from overlying epidermis in erythema nodo-
sum lesions were negative for both estrogen and pro-
gesterone receptors, like other normal human skin
8. How-
ever, the expression levels of progesterone receptor in 
other tissues of erythema nodosum patients remain un-
known. It has not been confirmed whether the effect of 
progesterone in erythema nodosum is direct or indirect. 
Further studies will be needed to address these questions.
Progesterone is critical in the process of endometrial 
preparation to maintain pregnancy. Either insufficient pro-
gesterone concentration or insufficient progesterone res-
ponse may lead to pregnancy loss. A recent study shows 
that normal endometrium is highly sensitive to very low 
levels of progesterone
9. Furthermore, no statistically signifi-
cant benefit has been observed in intramuscular proges-
terone administration over topical administration to vagi-
na
10. Since the quantity of hormones in oral contracep-
tives has been decreased after the 1980s, erythema nodo-
sum caused by oral contraceptive is now rare. Nowadays, 
the use of assisted reproductive therapy has become po-
pular. The advancement of related technology will hope-
fully lead to reduced dosage of progesterone required for 
endometrial preparation, and consequently lessen the 
incidence of erythema nodosum, as was the case with oral 
contraceptives. 
To our knowledge, assisted reproductive therapy-induced 
erythema nodosum has never been reported. However it 
should be considered as a possible adverse event in 
assisted reproductive therapy. 
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